Loading…
Corvus Pharmaceuticals, Inc. is projected to rise to $19.62 by 2027, a +52% move from its current price of $12.93. CRVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.35 | $12.94 | $13.56 | +0.07% |
| May 30 | $12.12 | $12.95 | $13.83 | +0.13% |
| May 31 | $11.95 | $12.96 | $14.05 | +0.20% |
| Jun 1 | $11.81 | $12.96 | $14.23 | +0.27% |
| Jun 2 | $11.69 | $12.97 | $14.40 | +0.34% |
| Jun 3 | $11.58 | $12.98 | $14.55 | +0.40% |
| Jun 4 | $11.48 | $12.99 | $14.70 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.48 | $12.99 | $14.70 | +0.47% |
| Week 2 | $10.96 | $13.05 | $15.54 | +0.95% |
| Week 3 | $10.59 | $13.11 | $16.24 | +1.42% |
| Week 4 | $10.29 | $13.18 | $16.86 | +1.90% |
| Week 5 | $10.05 | $13.24 | $17.45 | +2.39% |
| Week 6 | $9.83 | $13.30 | $18.00 | +2.87% |
| Week 7 | $9.64 | $13.36 | $18.52 | +3.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company is based in South San Francisco, California and was incorporated in 2014.
Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors. It is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor in Phase 2 trials for first-line renal cell cancer, and mupadolimab (CPI-006), a humanized monoclonal antibody in Phase 1 trials for non-small cell lung cancer.
Corvus has license agreements with Monash University to research, develop, and commercialize antibodies directed to CXCR2, with Vernalis to develop ciforadenant and license mupadolimab through Scripps for mupadolimab, and was incorporated in 2014 and is based in South San Francisco, California.
CRVS is the stock ticker for Corvus Pharmaceuticals, Inc. The current price is $12.61 and the market cap is $1.06B, with a rank of 2503. The overall price outlook is bullish in the long run, supported by a year-by-year forecast that shows rising averages from 2026 through 2050.
The 2026 forecast average matches the current price at $12.61, and the sequence of higher averages continues through 2027 ($19.46), 2028 ($20.87), 2029 ($24.31), 2030 ($21.85), 2031 ($23.54), 2032 ($32.92), 2033 ($38.04), 2034 ($44.39), 2035 ($48.81), 2040 ($80.83), and 2050 ($132.66). Max prices rise even more, with $37.17 in 2030, $171.67 in 2040, and $305.13 in 2050. The forecast also shows substantial returns, with ROI reaching 0% in 2026 and as high as 952.1% by 2050.
A major floor 40.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.1% below — buyers have tended to step in here.
The nearest ceiling, 38.1% above — a clean break opens room to run.
A major ceiling 97.4% above — clearing it would confirm fresh momentum.
Key CRVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.73 | Buy | $12.81 | Buy |
| MA 10 | $12.92 | Buy | $13.14 | Sell |
| MA 20 | $14.17 | Sell | $13.82 | Sell |
| MA 50 | $14.66 | Sell | $14.60 | Sell |
| MA 100 | $15.52 | Sell | $14.10 | Sell |
| MA 200 | $11.32 | Buy | $12.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.29 | Neutral |
| Stoch RSI (14) | 51.26 | Neutral |
| CCI (20) | -58.11 | Neutral |
| Williams %R (14) | -68.01 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -16.85 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 31.99 | Neutral |
| TRIX (15) | -0.57 | Sell |
| Awesome (5,34) | -2.14 | Sell |
| Ultimate (7,14,28) | 50.85 | Neutral |
| Momentum (10) | -3.04 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 12.91 | Buy |
| ADX (14) | 14.93 | Neutral |
| ATR (14) | 0.60 | Info |
The 30-day technical picture is bullish in sentiment, with RSI14 at 40 indicating room for movement either way. The SMA50 is $14.76 and the SMA200 is $11.24, suggesting a positive short-term trend as the 50-day average sits above the 200-day average. The price has traded in a 30-day range from $9.10 to $17.47, with a support level at $11.50 and a resistance at $17.85.
Annualized volatility is high at 90%, signaling elevated risk and potential for rapid price moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.50 | $12.93 | $21.14 | 0% | Neutral | |
| $14.49 | $19.62 | $28.65 | +52% | Bullish | |
| $14.69 | $20.92 | $32.28 | +62% | Bullish | |
| $16.32 | $24.26 | $39.07 | +88% | Bullish | |
| $14.37 | $22.22 | $37.09 | +72% | Bullish | |
| $14.64 | $23.46 | $40.41 | +81% | Bullish | |
| $19.27 | $31.96 | $56.58 | +147% | Bullish | |
| $21.81 | $37.38 | $67.86 | +189% | Bullish | |
| $24.33 | $43.07 | $79.97 | +233% | Bullish | |
| $25.74 | $46.99 | $89.11 | +263% | Bullish | |
| $36.08 | $76.33 | $157.88 | +490% | Bullish | |
| $57.15 | $127.00 | $292.09 | +882% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.50 | $12.93 | $15.48 | +0.00% |
| June 2026 | $11.40 | $13.60 | $16.75 | +5.15% |
| July 2026 | $11.36 | $13.75 | $17.32 | +1.12% |
| August 2026 | $12.04 | $14.74 | $18.89 | +7.18% |
| September 2026 | $12.48 | $15.43 | $20.05 | +4.69% |
| October 2026 | $12.01 | $14.98 | $19.70 | -2.92% |
| November 2026 | $11.85 | $14.90 | $19.81 | -0.52% |
| December 2026 | $12.42 | $15.73 | $21.14 | +5.60% |
Click any year to see its month-by-month CRVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CRVS price prediction for 2026 points to an average of $12.93 (low $6.50, high $21.14) — a potential gain of 0% on today's $12.93. A consolidation phase looks the most probable path here.
In 2027, CRVS is projected to trade between $14.49 and $28.65, averaging $19.62 — a potential gain of +52% from today's $12.93. That is up +52% on the projected 2026 average. Momentum favours further upside here.
Corvus Pharmaceuticals, Inc.'s 2028 outlook centres on $20.92, within a $14.69 to $32.28 range. That is up +7% on the projected 2027 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CRVS could reach as high as $39.07, with a base case around $24.26 and support toward $16.32 — roughly +88% from $12.93. Momentum favours further upside here.
Expect CRVS to range from $14.37 to $37.09 through 2030. The $22.22 average target implies a +72% move from current prices. That is -8% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The CRVS price prediction for 2031 points to an average of $23.46 (low $14.64, high $40.41) — a potential gain of +81% on today's $12.93. Momentum favours further upside here.
In 2032, CRVS is projected to trade between $19.27 and $56.58, averaging $31.96 — a potential gain of +147% from today's $12.93. That is up +36% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Corvus Pharmaceuticals, Inc.'s 2033 outlook centres on $37.38, within a $21.81 to $67.86 range. That is up +17% on the projected 2032 average. That marks a +189% change versus current levels. Momentum favours further upside here.
By 2034, CRVS could reach as high as $79.97, with a base case around $43.07 and support toward $24.33 — roughly +233% from $12.93. Buyers look set to stay in control over this stretch.
Expect CRVS to range from $25.74 to $89.11 through 2035. The $46.99 average target implies a +263% move from current prices. That is up +9% on the projected 2034 average. Momentum favours further upside here.
The CRVS price prediction for 2040 points to an average of $76.33 (low $36.08, high $157.88) — a potential gain of +490% on today's $12.93. Buyers look set to stay in control over this stretch.
In 2050, CRVS is projected to trade between $57.15 and $292.09, averaging $127.00 — a potential gain of +882% from today's $12.93. That is up +66% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CRVS today (≈ 77.33952 CRVS) could be worth
$9,821.76
+$8,821.76 (+882%) by 2050 · US Dollar
Based on the average projected CRVS price of $127 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRVSwould be worth at today's price.
$1,000 invested in CRVS on May 27, 2025 (≈ 272.479558 CRVS) would be worth
$3,523.16
+$2,523.16 (+252.3%) today · 3.52× · US Dollar
Based on a CRVS entry price of $3.67 vs. today's $12.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.19 | $1,060.71 | +6.1% |
| 1 month ago | $15.92 | $812.19 | -18.8% |
| 3 months ago | $18.26 | $708.11 | -29.2% |
| 6 months ago | $9.17 | $1,410.03 | +41.0% |
| 1 year ago | $3.67 | $3,523.16 | +252.3% |
| All time (5.0y) ago | $2.73 | $4,736.26 | +373.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRVS forecast.
Our base-case forecast reaches $26.00 around 2032.
Implied market cap at $26.00: $2.19B
The multi-year forecast depicts a bullish trajectory across the horizon. The average price is forecast to rise from $12.61 in 2026 to higher levels later, with 2027 at $19.46, 2030 at $21.85, 2040 at $80.83, and 2050 at $132.66. Max forecasted prices reach $37.17 in 2030, $171.67 in 2040, and $305.13 in 2050.
ROI progresses from 0% in 2026 to 54.3% in 2027, 65.5% in 2028, 92.8% in 2029, 73.3% in 2030, 86.7% in 2031, 161.1% in 2032, 201.7% in 2033, 252% in 2034, 287.1% in 2035, 541% in 2040, and 952.1% in 2050. The sentiment remains BULLISH across forecast years, but these are estimates and not guarantees, with actual results may vary.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $21.85, a min of $13.83, and a max of $37.17, with an ROI of 73.3% and a bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with average prices rising from $19.46 in 2027 to $132.66 on average by 2050 and ROI reaching up to 952.1%. Note that these are estimates and not guaranteed.
Yes. The max forecasted price reaches $171.67 by 2040 and $305.13 by 2050, while the 2030 max is $37.17. This indicates potential for prices above $100 in the forecast horizon.
The 2027 forecast shows an average price of $19.46, a min of $14.20, a max of $28.80, with a ROI of 54.3% and bullish sentiment.
Current price is $12.61 and market cap is $1.06B; the rank is 2503.
Corvus Pharmaceuticals, Inc. Community Discussion
0Share your Corvus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.